FDA Approval For Novartis’s Sickle Cell Treatment Adakveo
Gains Nod Ahead Of Global Blood Therapeutics’ Contender
One of a new wave of treatments, Novartis has focused on proving its drug cuts vaso-occlusive crises (VOCs), or pain crises.
You may also be interested in...
Oxbryta is the second new drug for sickle cell disease approved in just over one week, but it was approved with a broad label for sickle cell disease while Novartis' Adakveo was approved for pain crises.
Novartis and Roche will present alongside up-and-coming biotechs and microcaps..
The US firm has withdrawn its submission to get EU approval for Xyndari. After being turned down by the CHMP, Emmaus may try the decentralized approval procedure instead.